DR REDDY’S LANCHES DOCETAXEL IN US
Hyderabad, December 2014
Dr Reddy’s Laboratories Ltd has launched Docetaxel injection, a therapeutic equivalent of Taxotere, in the US market. The Hyderabad-based company had earlier obtained approval for the same from the US Food and Drug Administration. It is indicated for the treatment of certain types of cancers. The brand and generic had sales of $218 million in the US for the most recent 12 months ending in September 2014, according to IMS Health, Dr Reddy’s said in a release. Docetaxel injection is available in single dose, one vial formulation that does not require a prior dilution and is ready to add to the intravenous infusion solution. Business Line
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…